Set and setting, psychedelics and the placebo response: An extra-pharmacological perspective on psychopharmacology

Placebo response and set and setting are two literatures that address how non-pharmacological factors shape therapeutic outcomes. Placebo research, rooted in modern clinical trial methodology, examines how expectations, clinician behaviour and symbolic aspects of treatment contribute to improvement across many medical interventions. Set and setting arose within mid-twentieth century psychedelic research and contends that psychological disposition (set) and the physical/social environment (setting) powerfully modulate the subjective and clinical effects of psychoactive drugs. Hartogsohn frames the paper as an integrative, conceptual review that compares and contrasts placebo theory and set and setting theory, identifies their commonalities and differences, and explores how bringing them into dialogue could broaden understanding of extra-pharmacological influences on drug effects. The study aims to show how the two perspectives can complement one another theoretically and practically and to propose areas for empirical research into their interrelation, especially in the context of contemporary psychedelic research and clinical practice.

This paper is a conceptual and historical review rather than an empirical trial or systematic meta-analysis. Hartogsohn synthesises historical accounts, clinical reports and contemporary placebo literature to map the evolution of both placebo theory and set and setting concepts and to examine overlaps in mechanisms and implications. The approach emphasises comparative analysis: tracing origins, key findings and practical applications of each tradition, and then discussing theoretical bridges such as Daniel Moerman's "meaning response". The extracted text notes that a literature search did not find prior work explicitly linking placebo and set and setting theories; however, the paper does not report formal search methods, databases, inclusion criteria, or a PRISMA-style process. Because this is a narrative review, there is no primary sample, no quantitative synthesis, and no risk-of-bias assessment. Where empirical findings are cited, the review reports published results from historical studies, clinical trials and neurobiological research as described in the source literature.

Historical and conceptual account of placebo response: The review traces placebo from its linguistic origins to its modern role in clinical research. Beecher's 1955 claim that placebo accounted for 35% of drug effects is discussed and noted to have been invalidated methodologically, but his paper is credited with catalysing interest in placebo effects and the rise of randomised controlled trials. The literature cited indicates large and varied placebo contributions across conditions: in some analyses placebo effects have contributed twice as much as pharmacological effects to antidepressant outcomes; a positive general-practice consultation raised improvement rates by 25%; and non-adherence to placebo after myocardial infarction was associated with a doubling of mortality risk compared with adherence. Historical sham-surgery trials are presented as pivotal examples where placebo controls led to re-evaluation of invasive procedures (for example, bilateral internal mammary artery ligation for angina and sham neurosurgery for Parkinson's disease). Mechanisms and moderators of placebo: Expectation is foregrounded as central to placebo response, with variations in pill colour, size, brand and route of administration modulating effects (injections producing stronger placebo responses than pills). Social interaction and clinician demeanour matter: Kaptchuk's sham acupuncture work is cited, showing that prolonged interaction with a provider increased response rates from 44% to 62%. Physical environment and cultural context also alter outcomes — patients recovering in rooms with natural views recuperated faster than those facing brick walls, and placebo contributions to drug effects vary across countries (examples include ulcer trials in which Germany showed substantially higher placebo responses relative to other nations). Neurobiological correlates are reviewed: placebo activates endogenous dopamine release in the striatum, alters activity in the subthalamic nucleus in Parkinson's disease, changes brain metabolism in depression, modulates rostral anterior cingulate and lateral orbitofrontal cortices in anxiety, and placebo analgesia is mediated by endogenous opioids and can be blocked by naloxone. Account of set and setting: The review summarises mid-century psychedelic research that identified how psychological disposition and environmental factors shape drug effects. Hyde's experimental manipulation of staff behaviour (normal, friendly, cold) reportedly shifted the severity of negative LSD effects (scores cited as changing from 3.4 to 2.8 to 4) and showed greater negative reactions when subjects took the drug alone or were expected to perform tasks. Leary's formulation is presented: set comprises personality, preparation, expectation and intention; setting comprises physical, social and cultural surroundings. Clinical practices developed around psychedelics — use of music, lighting, images, preparation and non-intrusive therapeutic stance — are described as deliberate optimisation of set and setting. The review also notes the applicability of set and setting beyond psychedelics, citing examples such as the high spontaneous discontinuation of heroin use among Vietnam veterans (an 88% rate cited) and animal studies like Alexander's rat park experiments which show environment altering addiction behaviour. Bridging concepts and empirical leads: Moerman's "meaning response" is proposed as a conceptual bridge, reframing placebo effects as the health effects of meaning attached to treatments, symbols and rituals. The paper reports anecdotal but widespread claims that psychedelic experiences are rated by participants as among the most meaningful of their lives and suggests that psychedelics may amplify meaning perception and suggestibility, thereby potentiating placebo/meaning responses. Empirical suggestions include testing whether LSD can enhance placebo responses in pain and other conditions, investigating whether psychedelic modulation of brain regions implicated in placebo (for example, rostral anterior cingulate activation) occurs, and exploring genetic markers such as the COMT Val158Met polymorphism as predictors of placebo and set-and-setting responsiveness. The author emphasises that many putative healing reports following psychedelics remain anecdotal and that disentangling enhanced placebo effects from direct pharmacological effects will be methodologically challenging.

Hartogsohn interprets placebo response and set and setting as closely related expressions of a broader meaning-response phenomenon in which symbolic, psychological and contextual factors shape medical and psychological outcomes. The paper positions set and setting as a practical, user-oriented tradition that prescribes ways to optimise drug experiences, and placebo theory as a clinical-research tradition that documents and measures extra-pharmacological effects; each tradition can enrich the other. For example, set and setting practices used in psychedelic therapy provide concrete methods that could be translated into clinical settings to magnify beneficial meaning responses, while placebo research offers mechanistic and neuroscientific frameworks that might clarify how psychedelics modulate expectancy and suggestibility. The authors acknowledge important limitations and uncertainties. They note a scarcity of systematic empirical studies directly examining how psychedelics interact with placebo mechanisms, and they emphasise that many healing anecdotes are not controlled and should be treated cautiously. A methodological difficulty is highlighted: studying placebo-enhancement induced by an active psychedelic is intrinsically hard because the enhancer itself cannot be made inert, complicating attempts to isolate placebo-mediated from direct pharmacological effects. The review therefore calls for targeted empirical work — for instance, neuroimaging to test whether psychedelics augment activity in brain regions linked to placebo, clinical trials testing whether psychedelics raise placebo responsiveness in pain or mood disorders, and genetic studies investigating biomarkers like COMT Val158Met as predictors of both placebo and set-and-setting sensitivity. In applied terms, the paper suggests clinical and policy implications discussed by the author: integrating set-and-setting principles into treatment protocols may empower patients and practitioners, support harm-reduction efforts, and improve therapeutic outcomes as psychedelic research and drug-policy reform advance. The overall tone is one of cautious synthesis: the two literatures are complementary, but more rigorous empirical work is required to specify mechanisms and to guide safe, evidence-based implementation.

The review concludes that placebo response and set and setting can be seen as two related expressions of a single meaning-response process whereby non-material factors increase the likelihood of desired treatment outcomes. Hartogsohn argues that bringing the two perspectives together is mutually beneficial: set and setting provides practical methods for enhancing meaning response in clinical care, while placebo theory supplies explanatory and neuroscientific frameworks that may account for how psychedelics amplify suggestibility and meaning. The author calls for further research to clarify the precise relationships among placebo, set and setting and psychedelic pharmacology.